News

FDA approved once-daily oral enlicitide to lower LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia.

In this discussion during UV Safety Awareness Month, Suozzi highlights tips on reversing photodamage and sun protection misconceptions.

These modifiable factors, among others, directly contribute to 88.7% of all IHD deaths in 2023.

Massie, Donnelly, and Mankowski discuss how transplant center choice shapes kidney transplant evaluation and access.

Preliminary real-world data presented at EAACI 2026 found broad reductions in respiratory tract infections with OM-85, David Price, MD, said.

These positive topline findings highlight the investigational TYK2 inhibitor soficitinib (ICP-332) in patients with moderate-to-severe atopic dermatitis.

New data from the 45-patient Midpoint Cohort, despite not being powered for statistical significance, indicate a potentially substantial benefit.

FDA grants priority review to obinutuzumab, positioning it as the first potential approved therapy for primary membranous nephropathy.

5 dermatology takeaways from Maui Derm NP+PA Summer 2026, covering eczematous dermatitis, rosacea, blistering disease, hair loss, and pigmentation disorders.

Sripal Bangalore, MD, discusses his recent study proposing that early intervention can lead to better cardiovascular outcomes among these patients.

In this SDPA interview, Matthew Zirwas, MD, highlights key takeaways from his session 'Clinical Pearls for Optimizing Dermatologic Care.'

Beyond hemodynamics and treatment targets, McDevitt says the most important conversations APPs have with patients are often the ones that don't appear in guidelines.

Beyond hemodynamics and treatment targets, McDevitt says the most important conversations APPs have with patients are often the ones that don't appear in guidelines.

Kimberly Blumenthal, MD, explains how to risk-stratify drug allergy labels before surgery and identify likely culprits in perioperative reactions.

Jeffrey Weitz, MD, secretary general of the ISTH, discusses the recent analysis of the AXIOMATIC-TKR trial and its implications for FXIa inhibition.

In this SDPA Conference interview, Zirwas continues his discussion of increasing environmental impacts on rates of atopic dermatitis.

FIND-CKD demonstrated reduced eGFR decline in patients with nondiabetic CKD, providing new data for a population of >50% of CKD cases.

Matthew Zirwas, MD, speaks in this SDPA interview about evidence for atopic dermatitis being more of an environmental disease than a genetic one.

Combination therapy outperformed excimer light alone for vitiligo, according to Giovanni Leone, MD.

Wendy Stock, MD, on the recent FDA approval of Orca-T, a precision-engineered cell therapy for allogeneic transplant in adults with hematological malignancies

Bempikibart use led to clinically meaningful SALT improvements among those with alopecia areata in the phase 2a SIGNAL-AA study at 36 weeks.

In this podcast episode, 2 featured experts discuss AI, teledermatology, and strategies to reduce bias in skin of color dermatologic care.

Chiadi Ndumele, MD, PhD, breaks down the new guidelines and how they should be implemented in this sweeping document.

4-year PIONEER data show avapritinib sustains symptom control and improves emotional well-being and social functioning in ISM, per Thanai Pongdee, MD.

Stevan Gonzalez, MD, MS, explains patient characteristics and social determinants of health associated with chronic liver disease.

As July is UV Safety Awareness Month, key tips for addressing sun damage, skin cancer signs, photoaging, and more are highlighted in this discussion.

Martin discussed where hydroquinone still fits, why oral tranexamic acid remains underused, and how he decides when to escalate to procedural therapy.

Elafibranor achieved 85% ALP normalization at week 52 in the phase 3b ELSPIRE trial for primary biliary cholangitis.